583 related articles for article (PubMed ID: 23614718)
1. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
Kar P; Lipowsky R; Knecht V
J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
[TBL] [Abstract][Full Text] [Related]
2. Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease.
Kar P; Knecht V
J Phys Chem B; 2012 Mar; 116(8):2605-14. PubMed ID: 22280246
[TBL] [Abstract][Full Text] [Related]
3. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
4. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
5. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
Velazquez-Campoy A; Kiso Y; Freire E
Arch Biochem Biophys; 2001 Jun; 390(2):169-75. PubMed ID: 11396919
[TBL] [Abstract][Full Text] [Related]
6. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
[TBL] [Abstract][Full Text] [Related]
7. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
Meher BR; Wang Y
J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
[TBL] [Abstract][Full Text] [Related]
8. Multiple Molecular Dynamics Simulations and Free-Energy Predictions Uncover the Susceptibility of Variants of HIV-1 Protease against Inhibitors Darunavir and KNI-1657.
Wang R; Zheng Q
Langmuir; 2021 Dec; 37(49):14407-14418. PubMed ID: 34851643
[TBL] [Abstract][Full Text] [Related]
9. Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.
Kar P; Knecht V
J Comput Aided Mol Des; 2012 Feb; 26(2):215-32. PubMed ID: 22350569
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
12. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
[TBL] [Abstract][Full Text] [Related]
13. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
14. Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.
Hu G; Ma A; Dou X; Zhao L; Wang J
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240358
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
Tzoupis H; Leonis G; Megariotis G; Supuran CT; Mavromoustakos T; Papadopoulos MG
J Med Chem; 2012 Jun; 55(12):5784-96. PubMed ID: 22621689
[TBL] [Abstract][Full Text] [Related]
16. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR.
Ahmed SM; Kruger HG; Govender T; Maguire GE; Sayed Y; Ibrahim MA; Naicker P; Soliman ME
Chem Biol Drug Des; 2013 Feb; 81(2):208-18. PubMed ID: 23017010
[TBL] [Abstract][Full Text] [Related]
18. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
[TBL] [Abstract][Full Text] [Related]
19. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
20. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
Li D; Liu MS; Ji B; Hwang K; Huang Y
J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
